Contact Us | Print Page | Sign In | Register
News & Press: New from our Partners

News from our Partners: AAN Publishes Guideline on Disease-modifying Therapies for MS

Tuesday, May 1, 2018   (0 Comments)
Posted by: Elizabeth Porco
Share |
The AAN published a new guideline, Practice Guideline: Disease-modifying Therapies for Adults with Multiple Sclerosis, in Neurology® online on April 23, 2018, and in print in the April 24 issue. A press conference on the guideline was held on April 23 at the AAN Annual Meeting for national and international media.
  
According to the guideline, several disease-modifying therapies (DMTs) are effective in reducing the rate and risk of MS relapses and new or enlarging MRI-detected lesion formation. The question of whether to start a DMT, switch from one DMT to another, or stop a DMT depends on the benefits and risks of the medications and a personalized approach to each patient.
 
READ THE GUIDELINE
  
The guideline highlights key findings and provides guidance that clinicians will find helpful:
Careful risk management and personalization of treatment strategy are important.
For several DMTs, there is moderate to strong evidence supporting their use; the evidence from comparative efficacy trials is less strong. 
For some DMTs, the evidence is insufficient to determine efficacy but provides information regarding risk of adverse effects.
  
Read the guideline and access PDF summaries for clinicians and patients and a slide presentation set at AAN.com. For more information, email guidelines@aan.com or call (612) 928-6069.
  
CMSC Disclaimer 
The industry news information and articles are for informational purposes only, and are not intended to represent any trends, partnerships, commitments, or research of the Consortium of MS Centers or any of it's members in any way whatsoever, nor should any party be libel in any way to the reader or to any other person, firm or corporation reading this industry news section. Although the CMSC site includes links providing direct access to other Internet sites, CMSC takes no responsibility for the content or information contained on those other sites, and does not exert any editorial or other control over those other sites. CMSC is providing information and services on the Internet as a benefit and service in furtherance of CMSC's nonprofit and tax-exempt status. CMSC makes no representations about the suitability of this information and these services for any purpose.


The Consortium of Multiple Sclerosis Centers

3 University Plaza Drive, Suite 116 Hackensack, NJ 07601

Tel: 201.487.1050 | Fax: 862.772.7275

info@mscare.org